On March 17, 2026, SAB Biotherapeutics, Inc. announced an underwritten offering of 19,324,677 shares of common stock at $3.85 each and pre-funded warrants, estimating net proceeds of approximately $69.7 million, with the offering closing on March 19, 2026.